If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more.
IAEA Radioisotopes and Radiopharmaceuticals Series No. 8
English STI/PUB/2031 | 978-92-0-139322-7
129 pages | 3 figures | € 46.00 | Date published: 2023EPUB format available (7.41 MB)
Preclinical or nonclinical evaluation is an integral part of the development of any drug. The process of developing a new radiopharmaceutical includes rigorous testing before it can be cleared for use in humans. There must be in-depth characterization of its behaviour to assess its safety and suitability for the intended clinical application. This publication provides a baseline guide for preclinical evaluation of radiopharmaceuticals that will give its readers a general review of the requirements of a facility and insight into the various scientific activities that constitute this process. The principles and protocols discussed herein will provide guidelines for biological assessment of candidate compounds, which are consistent with the principles of good laboratory practices to generate valid nonclinical scientific data towards approval for clinical translation. This publication is intended not only for researchers engaged in radiopharmaceutical development, but also for the Member States planning to set up or upgrade facilities for radiopharmaceuticals’ research.
More Information on reusing IAEA copyright material.
Orders and requests for information may also be addressed to:
Publishing Section
International Atomic Energy Agency
Vienna International Centre
PO Box 100, A-1400 Vienna,
Austria
Tel.: +43 1 2600 22529, +43 1 2600 22530
Email: sales.publications@iaea.org
